Rare Immunology News

Advertisement

Spotlight On

Alopecia universalis

Alopecia universalis, also known as alopecia areata universalis, is a medical condition involving the loss of all body hair, including eyebrows, eyelashes, chest hair, armpit hair, and pubic hair

Prevalence

1-5 / 1,000,000

33,100-165,500

US Estimated

51,350-256,750

Europe Estimated

Age of Onset

ICD-10

L63.1

Inheritance

This condition does not appear to have a clear pattern of inheritance.

 

Rare View

Alopecia areata (AA) is a chronic, autoimmune disorder of non-scarring hair loss mediated by T-lymphocytes against the hair follicular unit. Alopecia totalis (AT) is a condition characterized by the complete loss of hair on the scalp. It is an advanced form of alopecia areata a condition that causes round patches of hair loss.

5 Facts you should know

FACT

1

It is the most severe form of alopecia areata

FACT

2

A large proportion of patients will obtain at least transient recovery periods of partial or total hair regrowth

FACT

3

It is characterized by the involvement of multiple inflammatory cytokines such as tumor necrosis factor-alpha and multiple interferons

 

FACT

4

AU has been observed to cause a significant impact on patients’ confidence, self-esteem, and socialization

 

FACT

5

People with AU are usually healthy - and have no other symptoms and a normal life expectancy

Alopecia universalis is also known as...

Alopecia universalis is also known as:

  • Congenital and Genetic Diseases
  • Immune System Diseases
  • Skin Diseases
     
     

What’s your Rare IQ?

Which of the following associated symptoms is not usually associated with patients experiencing Alopecia?

Common signs & symptoms

Absent eyebrow

Absent eyelashes

Patchy alopecia

Alopecia totalis

Autoimmunity

Multifactorial inheritance

Nail pits

Trachyonychia

Current treatments

No therapy has been found to work for everyone who has alopecia universalis (AU) which makes managing AU challenging. Although multiple treatments have been explored, no therapy is currently approved by the United States Food and Drug Administration (FDA). Some promising therapies include:

Diphenylcyclopropenone (DPCP)

Squaric acid dibutylester (SADBE)

Photodynamic therapy

Steroids

Cyclosporine in combination with methylprednisolone (a steroid)

Top Clinical Trials

Top Treatments in Research